Benzinga | Oct 27, 2021 07:15AM EDT

EXCLUSIVE: Pasithea Therapeutics's Subsidiary Pasithea Clinics Announces Successful Treatment Of First Patients In The UK With Ketamine Infusion Therapy

Miami Beach, FL / October 27, 2021 -- Pasithea Therapeutics Corp. (Nasdaq:

KTTA) ("Pasithea" or the "Company"), a novel biotechnology company focused

on the research and discovery of new and effective treatments for psychiatric

and neurological disorders, today announced that Pasithea Clinics, its wholly

owned subsidiary has administered intravenous ("IV") ketamine therapy to its

first patients. In sub-anesthetic doses, ketamine has shown to be highly effective

at treating some psychiatric disorders, such as treatment-resistant depression

and post-traumatic stress disorder.

"With major depression the leading cause of long-term disability worldwide and

mental health cases on the rise, new therapies are urgently needed for patients

who do not respond to traditional treatments. Today, we are thrilled to announce

that we administered our first IV ketamine infusion therapy to patients with

treatment-resistant depression," stated Dr. Tiago Reis Marques, CEO of Pasithea

Therapeutics.

"This is a significant milestone for Pasithea Clinics and for patients in the U.K.

suffering with mental health conditions. Decades of evidence supports the

efficacy of ketamine in improving symptoms for some mental health disorders,

and studies have shown that up to 70% of those who receive IV ketamine

treatment will eventually show a clinical response. We are excited to continue

providing treatment to patients deemed eligible to receive it," concluded Dr. Reis

Marques.

Ketamine is a U.S. Food and Drug Administration ("FDA") approved drug

introduced as an anesthetic more than 50 years ago. It has recently been

repurposed in significantly lower doses for the treatment of psychiatric disorders

and is now gaining ground as a promising treatment for mental health disorders.

In certain psychiatric conditions, such as treatment-resistant depression ("TRD")

and post-traumatic stress disorder ("PTSD"), it has shown remarkable efficacy

and a rapid and sustained effect.

Pasithea has clinical partnerships to administer its IV ketamine treatment. In the

U.K., it has partnered with ZEN Healthcare -- a network of health clinics in

London. In the U.S., it has partnered with The IV Doc, Inc. to provide in-home IV

ketamine infusions. Both partnerships offer rapid exposure and expansion

opportunities.



About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused

on the research and discovery of new and effective treatments for psychiatric

and neurological disorders. With an experienced team of experts in the fields

of neuroscience and psychopharmacology, Pasithea is developing new

molecular entities for the treatment of psychiatric and neurological disorders.

Pasithea is also focused on addressing the needs of patients currently

suffering with mental illness by providing access to IV ketamine infusions

both in clinics and in-home settings.

Forward Looking Statements

This press release contains statements that constitute "forward-looking

statements." Forward-looking statements are subject to numerous conditions,

many of which are beyond the control of the Company. While the Company

believes these forward-looking statements are reasonable, undue reliance should

not be placed on any such forward-looking statements, which are based on

information available to the Company on the date of this release. These forward-

looking statements are based upon current estimates and assumptions and are

subject to various risks and uncertainties, including, without limitation, those set

forth in the Company's filings with the SEC. Thus, actual results could be

materially different. The Company undertakes no obligation to update these

statements whether as a result of new information, future events or otherwise,

after the date of this release, except as required by law.